Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
BRIDGEWATER, N.J. - On Thursday, Amneal Pharmaceuticals (NASDAQ:AMRX) reported third-quarter earnings that exceeded analyst expectations and raised its full-year profit outlook.
The company’s shares rose 6.81% in pre-market trading after the release.
The generic and specialty pharmaceutical manufacturer posted adjusted earnings of $0.17 per share for the third quarter, beating the analyst consensus of $0.14. Revenue climbed 12% YoY to $785 million, surpassing the $769.46 million estimate. The company’s strong performance was driven by growth across all three business segments, with its AvKARE distribution unit showing the strongest growth at 24%.
"Amneal delivered another strong quarter and updated our 2025 outlook, underscoring the strength of our diversified business and the ongoing evolution of our portfolio," said Chirag and Chintu Patel, Co-Chief Executive Officers.
The company raised its full-year adjusted earnings guidance to $0.75-$0.80 per share from the previous $0.70-$0.75 range, while maintaining its revenue forecast of $3.0-$3.1 billion. Amneal also increased its adjusted EBITDA guidance to $675-$685 million from $665-$685 million previously.
Specialty segment revenue increased 8% driven by key branded products, including CREXONT for Parkinson’s disease and UNITHROID. The Affordable Medicines segment also grew 8%, benefiting from strong performance of complex products and new launches. The company recently launched BREKIYA in the migraine space and completed a refinancing that positions it well for future growth.
Net income attributable to Amneal was $2 million in the quarter compared to a net loss of $0.2 million in the same period last year, reflecting higher revenue and gross profit, partially offset by increased operating expenses.
"Together with our recent refinancing, Amneal is closing 2025 and entering 2026 from a position of strength and momentum," the Patel brothers added.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.